Latest Transformation News

Horizon Minerals is progressing its Pre-Feasibility Study to convert the Black Swan plant to gold production, aiming for a 1.5Mtpa throughput and a Financial Investment Decision by early 2026.

First Graphene Limited’s partnership with Halocell Energy and QUT has yielded a breakthrough in perovskite solar cells, doubling efficiency to 30.6% while cutting production costs by up to 80%. This innovation paves the way for scalable, low-cost solar solutions across multiple industries.

Meridian Energy posted a significant net loss for FY25 due to severe droughts and gas shortages but pushed ahead with renewable investments and maintained shareholder dividends.

RPMGlobal completes its transition to a pure-play software company, reporting robust FY25 results driven by subscription revenue growth and a $63.6 million Advisory divestment. The company projects significant margin expansion and revenue growth in FY26 backed by a $200 million contract backlog.

RPMGlobal Holdings Limited reported a striking 448% increase in net profit for FY2025 alongside significant changes in its subsidiary portfolio, signaling a transformative year for the software services company.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Intelligent Monitoring Group Limited (IMG) reported a 44% revenue surge to $174.9 million in FY25, driven by four key acquisitions and organic growth, while investing heavily in AI-powered video monitoring technology.

Scentre Group reported a robust half-year result with profit after tax surging to $782.2 million and Funds From Operations rising 3.2%, underpinned by strong retail sales and near-record occupancy. The Group also advanced a $4 billion development pipeline and sold a 25% stake in Westfield Chermside, maintaining management control.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.